Hubin Yin

Hubin Yin

Auto-generated profile, based on publicly available information

Hubin Yin

Department of Urology The First Affiliated Hospital of Chongqing Medical University Chongqing China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2026 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
XXXiao Xiao
Xiao Xiao
XLXingshan Lu
Xingshan Lu
JPJunxiong Peng
Junxiong Peng
LLLi Li
Li Li
XBXuesong Bai
Xuesong Bai
YHYunfeng He
Yunfeng He
Bladder cancer (BCa) remains a major global health challenge with high recurrence and progression rates. Although metabolic reprogramming is recognized as

21 August 2026 in Cancer Science
Verified
Journal Article
Open access
PDF file
JGJunlin Gan
Junlin Gan
XBXuesong Bai
Xuesong Bai
AZAijie Zhang
Aijie Zhang
FLFei Lin
Fei Lin
HTHang Tong
Hang Tong
HYHubin Yin
Hubin Yin
Tripartite motif‐containing 59 (TRIM59) is an E3 ubiquitin ligase implicated in multiple malignancies, but its role in bladder cancer (BLCA) remains incompletely understood. In this study, we identified TRIM59 as a clinically relevant oncogenic driver in BLCA through integrated transcriptomic, clinical, and functional analyses. TRIM59 was significantly upregulated in BLCA tissues and cell lines, and high TRIM59 expression was associated with advanced stage, higher grade, recurrence, and poor prognosis. Functionally, TRIM59 promoted BLCA proliferation, cell‐cycle progression, migration, invasion, and metastatic colonization in vitro and in vivo. Mechanistically, TRIM59 directly interacted with PTRF/Cavin‐1 and induced its RING domain‐dependent K48‐linked polyubiquitination and proteasomal degradation. Additional mutagenesis analyses identified K98, K122, K152, and K317 as major ubiquitination sites on PTRF. In contrast to the oncogenic role of TRIM59, PTRF was downregulated in BLCA and exhibited tumor‐suppressive properties. PTRF restoration attenuated TRIM59‐driven proliferation, invasion, and epithelial‐mesenchymal transition, whereas PTRF depletion partially rescued the inhibitory effects of TRIM59 silencing. Further analyses showed that PTRF restrains AKT phosphorylation and suppresses MYC transcriptional activity, thereby limiting c‐Myc‐driven proliferative signaling. Collectively, these findings define a previously unrecognized TRIM59–PTRF–AKT/c‐Myc axis that drives BLCA progression and highlight TRIM59 as a potential prognostic biomarker and therapeutic target.